FLGT NASDAQ
Fulgent Genetics, Inc.
1W: +1.8%
1M: -7.4%
3M: +5.4%
YTD: -19.1%
1Y: -12.8%
3Y: -18.5%
5Y: -75.1%
$20.70
+0.48 (+2.37%)
Weekly Expected Move ±7.0%
$17
$19
$20
$22
$23
Credit Risk of going bust: lower than 77% of companies Debt: 1.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down 99.9%), Fulgent Genetics, Inc. would be worth roughly what it owes.
Total debt $9.4M against a stock market value of $569.6M.
Distance to default 8.89 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.2M (short-term plus half of long-term), stock volatility 67.3%; Altman Z'' 14.45. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down 99.9%), Fulgent Genetics, Inc. would be worth roughly what it owes.
Total debt $9.4M against a stock market value of $569.6M.
Distance to default 8.89 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.2M (short-term plus half of long-term), stock volatility 67.3%; Altman Z'' 14.45. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
24 relationships24
As Filer
counterparties named
0
As Counterparty
mentioned by others
5
Rel. Types
2022-04-18
Earliest Filing
2026-03-17
Latest Filing
target: 16
investor: 3
acquirer: 2
partner: 2
supplier: 1
Counterparties (Filed by FLGT)
24 relationshipsCompanies named in FLGT's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Inform Diagnostics, Inc. | — | acquirer | Wholly owned subsidiary of Fulgent Genetics, Inc. that acquired Bako Diagnostics and StrataDx. | 2026-03-17 | View |
| Consonance Capital Partners | — | investor | Investor in Bako Diagnostics and StrataDx. | 2026-03-17 | View |
| Fulgent Therapeutics, LLC | — | partner | Party to agreements for specific transaction sections. | 2026-03-17 | View |
| GBRL Consulting, LLC | — | target | Seller of podiatric pathology assets. | 2026-03-17 | View |
| Podceuticals L.L.C. | — | target | Seller of podiatric pathology assets. | 2026-03-17 | View |
| Bakotic Pathology Associates, L.L.C. | — | target | Seller of dermatopathology and podiatric pathology assets. | 2026-03-17 | View |
| Dermatopathology Experts, LLC | — | target | Seller of StrataDx equity. | 2026-03-17 | View |
| BPA Holding Corp. | — | target | Seller of Bako Diagnostics assets and StrataDx equity. | 2026-03-17 | View |
| Bako Pathology Holdings Corp. | — | target | Seller of Bako Diagnostics assets and StrataDx equity. | 2026-03-17 | View |
| Bako Pathology LP | — | target | Seller of Bako Diagnostics assets and StrataDx equity. | 2026-03-17 | View |
| Inform Diagnostics, Inc. | — | acquirer | Wholly owned subsidiary of Fulgent Genetics, Inc. acquiring Dermatopathology Experts, LLC and assets from Bako Pathology | 2025-12-22 | View |
| GBRL Consulting, LLC | — | target | Seller entity selling assets related to consulting services. | 2025-12-22 | View |
| Podceuticals L.L.C. | — | target | Seller entity selling assets related to therapeutic products. | 2025-12-22 | View |
| Bakotic Pathology Associates, L.L.C. | — | target | Seller entity selling assets related to dermatopathology and podiatric pathology. | 2025-12-22 | View |
| Fulgent Therapeutics, LLC | — | partner | Entity providing limited guarantee for specific sections of the PSA and APA. | 2025-12-22 | View |
| Dermatopathology Experts, LLC | — | target | Target company whose equity interests are being sold in the PSA. | 2025-12-22 | View |
| BPA Holding Corp. | — | target | Seller entity selling equity interests and assets. | 2025-12-22 | View |
| Bako Pathology Holdings Corp. | — | target | Holdings entity of the Seller group selling equity interests and assets. | 2025-12-22 | View |
| Bako Pathology LP | — | target | Parent entity of the Seller group selling equity interests and assets. | 2025-12-22 | View |
| E&E Plaza LLC | — | supplier | Lessor in commercial lease agreement for headquarters property | 2023-01-12 | View |
| Avista Capital Partners IV GP, L.P. | AVA | investor | Stockholder representative for Symphony Buyer, Inc. securityholders. | 2022-04-26 | View |
| Symphony Buyer, Inc. | — | target | Target company acquired by Fulgent Therapeutics LLC in a merger transaction. | 2022-04-26 | View |
| Inform Diagnostics | — | target | Target of acquisition by Fulgent Genetics for approximately $170 million | 2022-04-18 | View |
| Avista Capital Partners | AVA | investor | Private equity firm and portfolio company owner of Inform Diagnostics | 2022-04-18 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-07-30 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-06-02 | Other Events; Exhibits | View | |
| 2026-05-21 | Other Events; Exhibits | View | |
| 2026-05-14 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-01 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-03-17 | Entry into Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Regula | Agreement Acquisition | View |
| 2026-02-27 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-12-22 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-11-07 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-10-20 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-01 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-05-15 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-02 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-02-28 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-11-08 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-05-16 | Submission of Matters to a Vote of Security Holders | View | |
| 2024-05-03 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2023-11-03 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2023-08-04 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2023-05-18 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR